{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-227977","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.938910+00:00","generated_at":"2026-05-31T01:10:51.345527+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cue Biopharma prices $12M public offering of stock and warrants, extends cash runway into Q4 2025","bullets":["10.6M shares of common stock and 2.9M common stock warrants offered at $0.50 per unit; pre-funded warrants for 12.4M shares at $0.499.","Net proceeds estimated at $10.7M after underwriting discounts and expenses.","Oppenheimer & Co. is sole book-running manager; closing expected September 30, 2024.","Cash runway extended into fourth quarter of 2025, based on current plans.","Warrants: pre-funded exercisable at $0.001, common stock warrants at $0.50, expire in five years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-227977","json":"https://secwatch.observer/filing/0001193125-24-227977.json","markdown":"https://secwatch.observer/filing/0001193125-24-227977.md","text":"https://secwatch.observer/filing/0001193125-24-227977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312524227977/0001193125-24-227977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312524227977/d856255d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:10:51.345527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}